AbbVie Secures EU Approval for RINVOQ® to Treat Severe Alopecia Areata in Adolescents and Adults

AbbVie Secures EU Approval for RINVOQ®

On July 29, 2026, AbbVie (NYSE: ABBV) proudly announced that the European Commission (EC) has granted approval for RINVOQ® (upadacitinib), available in 15 mg and 30 mg doses to be taken once daily. This approval is a significant milestone for adult and adolescent patients aged 12 years and older suffering from severe alopecia areata (AA).

Tackling Severe Alopecia Areata

The importance of this approval cannot be overstated. A multifaceted autoimmune condition, alopecia areata is known for its unpredictable nature, leading to varying degrees of hair loss. This condition can manifest as anything from sudden, round bald patches to complete loss of all body hair, including eyebrows and eyelashes, impacting both the physical and psychological well-being of those affected.

Dr. Roopal Thakkar, executive vice president and chief scientific officer at AbbVie, emphasized that the EC's decision signifies a new treatment option for individuals battling severe alopecia areata in Europe. Not only does RINVOQ demonstrate clinically meaningful scalp hair regrowth, but it also addresses the often-overlooked stigma associated with this condition. For many patients, this treatment presents a valuable alternative to help alleviate the physical and mental burdens they face.

Clinical Evidence Behind the Approval

The approval by the European Commission is based on robust data from the pivotal Phase 3 UP-AA clinical trial program, which highlighted RINVOQ's effectiveness in promoting hair regrowth. Participants in this study showed statistically significant improvements, whereby a substantial number achieved the primary endpoint of a Severity of Alopecia Tool (SALT) score of ≤ 20 within 24 weeks.

In addition, the trials demonstrated that both the 15 mg and 30 mg doses of RINVOQ led to a higher proportion of patients reaching at least 80% scalp hair coverage when compared to placebo. Notably, RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT score of 0) at the 24-week mark. Key secondary endpoints, such as improvements in eyebrow and eyelash growth, were also met, showcasing RINVOQ's comprehensive therapeutic potential.

Challenges in Treating Alopecia Areata

Alopecia areata often poses considerable challenges, both in treatment and management. Its unpredictable nature complicates the treatment landscape, making it essential to consider new therapeutic options such as RINVOQ. Dr. Thierry Passeron, professor and chair at the Department of Dermatology, Université Côte d'Azur, highlighted that the results from the UP-AA program reveal clinically significant scalp hair regrowth, making RINVOQ an important treatment avenue for patients in need.

Despite its immune-mediated complexities, alopecia areata is frequently misconstrued as merely a cosmetic issue. In reality, it carries a considerable impact on patients’ lives, contributing to both psychological distress and social implications. Data suggests that individuals with alopecia areata face an up to 40% higher risk of developing new-onset depression and anxiety compared to the general population, with this risk noticeably heightened in women.

Future of RINVOQ in Treating Alopecia Areata

RINVOQ is also approved for treating additional conditions in the European Union, including atopic dermatitis, various types of arthritis, and ulcerative colitis, showcasing its broad therapeutic capabilities. As clinical trials continue, RINVOQ may provide further insights into its effectiveness across various immune-mediated inflammatory diseases.

In conclusion, AbbVie’s introduction of RINVOQ represents a notable advancement in the treatment of severe alopecia areata. The European Commission's approval not only opens new opportunities for affected individuals but also strengthens AbbVie’s commitment to revolutionizing care for patients with immune-mediated conditions across the globe. As more patients gain access to this treatment, we can only hope for a positive shift in managing the multifaceted challenges posed by alopecia areata.